Myelodysplastic Syndromes

Latest News

$Patients with RS-negative low-risk MDS who were relapsed or refractory to or ineligible for ESAs appeared to experience clinical benefit with imetelstat treatment in a post hoc analysis. | Image credit: fotogurmespb - stock.adobe.com$

Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS

By Ashley Chan

July 1st 2025

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com

Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

By Rose McNulty

June 18th 2025

The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

By Rose McNulty

June 5th 2025

Genetic testing for hereditary forms of solid tumors led to an unsuspected diagnosis of MDS, a recent case report described. | Image Credit: Dr_Microbe - stock.adobe.com

Genetic Testing for Hereditary Cancer Identifies Case of MDS

By Rose McNulty

May 29th 2025

Even among patients with MDS and anemia with a high transfusion burden, 7 of 12 patients who responded experienced responses lasting longer than 6 months. | Image Credit: Eleni - stock.adobe.com

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

By Rose McNulty

May 22nd 2025

<1 2 3 4 5 6

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions